We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Asensus Surgical Inc
19 own
21 watching
Current Price
$0.8
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
189.43M
52-Week High
0.93
52-Week Low
0.28
Average Volume
1.43M
Dividend Yield
--
P/E Ratio
--
Market Capitalization189.43M52-Week High0.9352-Week Low0.28Average Volume1.43MDividend Yield--P/E Ratio--What does the Asensus Surgical Inc do?
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company s products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More
How much money does Asensus Surgical Inc make?
News & Events about Asensus Surgical Inc.
Globe Newswire
2days ago
RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced that the Company will host ...
Globe Newswire
9days ago
Expanded Intelligent Surgical Unit (ISU) capabilities include 3D measurement, digital tagging, image enhancement, and enhanced camera control, for our European customers
The Senhance Surgical System
The Senhance Surgical System is powered by the Intelligent Surgical Unit, enabling real-time ...
Globe Newswire
1month ago
Continued expansion of the Senhance Program in the regionRESEARCH TRIANGLE PARK, N.C., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-...
Globe Newswire
4 months ago
Senhance Surgical System
Senhance Surgical System is the first of its kind digital laparoscopic platform providing surgical assurance through haptic feedback, eye-tracking camera control, 3D visualization and 3mm instruments.
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- ...
Frequently Asked Questions
Frequently Asked Questions
What is Asensus Surgical Inc share price today?
Can Indians buy Asensus Surgical Inc shares?
How can I buy Asensus Surgical Inc shares from India?
Can Fractional shares of Asensus Surgical Inc be purchased?
What are the documents required to start investing in Asensus Surgical Inc stocks?
What is today’s traded volume of Asensus Surgical Inc?
What is today’s market capitalisation of Asensus Surgical Inc?
What is the 52-Week High and Low Range of Asensus Surgical Inc?
What percentage is Asensus Surgical Inc down from its 52-Week High?
What percentage is Asensus Surgical Inc up from its 52-Week Low?
Current Price
$0.8
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.